Insulet (NASDAQ:PODD) Shares Sold Off by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insulet stock on September 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Insulet Price Performance

Shares of PODD stock opened at $133.93 on Thursday. The firm has a fifty day moving average of $140.57 and a two-hundred day moving average of $157.42. The firm has a market cap of $9.29 billion, a P/E ratio of 25.03, a P/E/G ratio of 1.09 and a beta of 1.11. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company’s quarterly revenue was up 23.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on PODD. Stifel Nicolaus lowered their target price on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Citigroup boosted their price objective on shares of Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Barclays upgraded shares of Insulet to a “hold” rating in a research note on Wednesday, October 7th. Royal Bank Of Canada cut their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, BTIG Research cut shares of Insulet from a “buy” rating to a “neutral” rating in a report on Thursday, August 6th. Thirteen research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $186.68.

Institutional Trading of Insulet

A number of large investors have recently modified their holdings of PODD. MV Capital Management Inc. acquired a new position in shares of Insulet during the 4th quarter valued at $29,000. Elevation Wealth Partners LLC raised its stake in shares of Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 104 shares in the last quarter. Sound Income Strategies LLC lifted its holdings in shares of Insulet by 4,620.0% in the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 231 shares during the period. State of Wyoming lifted its holdings in shares of Insulet by 34.6% in the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after buying an additional 73 shares during the period. Finally, Continuum Advisory LLC bought a new position in Insulet during the second quarter valued at about $46,000.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.